

信使核糖核酸新冠疫苗  
COVID-19 mRNA Vaccine

# Comirnaty 「復必泰」

(BNT 162b2)

2021 年 6 月 14 日起，  
Comirnaty 將獲准用於 12 歲及以上人士，包括 12 歲至 15 歲的青少年。

此項批准是基於疫苗在臨床試驗中顯示出良好的安全性和有效性，且副作用較輕微。此外，疫苗在青少年中的安全性和有效性也得到了證實。

Comirnaty 是一種 mRNA 疫苗，由德國藥廠 BioNTech 和復星醫藥聯合研發。該疫苗在臨床試驗中顯示出良好的安全性和有效性，且副作用較輕微。此外，疫苗在青少年中的安全性和有效性也得到了證實。

此項批准是基於疫苗在臨床試驗中顯示出良好的安全性和有效性，且副作用較輕微。此外，疫苗在青少年中的安全性和有效性也得到了證實。

此項批准是基於疫苗在臨床試驗中顯示出良好的安全性和有效性，且副作用較輕微。此外，疫苗在青少年中的安全性和有效性也得到了證實。

**From 14 June 2021,  
Comirnaty is given to adults and adolescents from 12 years of age and older.**

For very common side effects, such as injection site pain and swelling, tiredness, headache, muscle pain, chills, joint pain, diarrhoea and fever, some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

Very rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have been reported after vaccination with Comirnaty. The cases have primarily occurred within two weeks following vaccination, more often after the second vaccination, and more often occurred in younger men.

Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

Adolescents and young adults should avoid strenuous exercise for one week after Comirnaty vaccination.

آخر تحديث: 2021 年 8 月 6 日 | Version date: 6 August 2021

